Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PDZ and LIM domain protein 5 (PDLIM5), also known as Enigma homolog (ENH), is a cytoplasmic protein with a PDZ domain at the N-terminus and three LIM domains at the C-terminus, primarily expressed in heart and skeletal muscle. PDLIM5 acts as a scaffolding protein associated with the actin cytoskeleton, mediating protein-protein interactions important for cytoskeletal architecture, cell adhesion, and signaling. It plays crucial roles in heart and muscle development by scaffolding protein kinase C (PKC) to the Z-disk of cardiomyocytes and regulates cell migration, proliferation, and differentiation. PDLIM5 also sequesters certain nuclear transcription factors in the cytoplasm, thereby modulating gene expression relevant to development and disease. Altered PDLIM5 expression has been implicated in tumorigenesis, metastasis, cardiac hypertrophy, and neuropsychiatric disorders. Multiple transcript variants/isoforms exist with potential tissue- and function-specific roles. However, PDLIM5 is not currently recognized as a direct therapeutic target, and no drugs are known to modulate its function clinically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PDZ and LIM domain protein 5 (PDLIM5).